Thermo Fisher Scientific Redeemable noncontrolling interests in subsidiaries decreased by 0.8% to $121.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 5.5%, from $128.00M to $121.00M. This is a positive signal — lower values indicate better performance for this metric.
An increase represents a potential future cash obligation that could impact liquidity or capital allocation.
This represents the portion of equity in a subsidiary that is held by third parties but is subject to redemption feature...
Specific to companies with complex joint venture or subsidiary structures; peers with similar structures will report this similarly.
other_redeemable_noncontrolling_interest_equity_carrying_amount| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $122.00M | $113.00M | $117.00M | $119.00M | $116.00M | $123.00M | $113.00M | $118.00M | $118.00M | $119.00M | $115.00M | $127.00M | $120.00M | $128.00M | $126.00M | $129.00M | $122.00M | $121.00M |
| QoQ Change | — | -7.4% | +3.5% | +1.7% | -2.5% | +6.0% | -8.1% | +4.4% | +0.0% | +0.8% | -3.4% | +10.4% | -5.5% | +6.7% | -1.6% | +2.4% | -5.4% | -0.8% |
| YoY Change | — | — | — | — | -4.9% | +8.8% | -3.4% | -0.8% | +1.7% | -3.3% | +1.8% | +7.6% | +1.7% | +7.6% | +9.6% | +1.6% | +1.7% | -5.5% |